Tumor Necrosis Factor (TNF) Inhibitor Drugs Market - Autoimmune Disease Treatments | Detailed Study by Coherent Market Insights with Upcoming Trends
Global Tumor Necrosis Factor (TNF) Inhibitor Drugs market analysis
Overview
Inflammatory arthritis is treated with TNF (Tumor Necrosis Factor) inhibitors, which are a type of drug. TNF-alpha, a part of the immune system that causes inflammation in the body, is the target of these drugs. Remicade (Infliximab), golimumab, humira (adalimumab), cimzia (certolizumab), and Etanercept (Enbrel) are the five inhibitors currently on the market (simponi). Only autoimmune disorders including rheumatoid arthritis, Crohn's disease, and psoriasis are treated with these medications.
Get Sample PDF Including COVID-19 Impact Analysis: https://www.coherentmarketinsights.com/insight/request-pdf/3463
The U.S. FDA (Food and Drug Administration) has authorised biosimilars for a drug that is already on the market. Amgen Inc.'s etanercept (brand name: Enbrel) has two biosimilars: etanercept- szzs (erelzi) manufactured by Novartis AG and etanercept- ykro (eticovo) manufactured by Samsung Bioepis Co., Ltd. The use of biosimilars has the benefit of being less expensive than the original drug. Merck & Co., Johnson & Johnson Services, Inc., Novartis AG, and others, are some of the suppliers in the global tumor necrosis factor (TNF) inhibitors drugs market.
Drivers
During the forecast period, major companies will be developing and manufacturing new medicines as well as biosimilars in the global tumor necrosis factor (TNF) inhibitor drugs market. Over the projected period, this factor is expected to stimulate growth of the global tumor necrosis factor (TNF) inhibitor drugs market. Eticovo, a second biosimilar of Enbrel developed by Samsung Bioepis Co., Ltd, was authorised by the US Food and Drug Administration in May 2019 and costs US$ 1,500 less than the generic medication (Enbrel costs about US$ 5,000 for a monthly subscription).
Furthermore, Novartis AG's Erelzi, the first biosimilar of Enbrel, is available in the shape of a sensoready pen with an inbuilt autoinjector, which is useful for patients with arthritis who are unable to function properly with their limbs. This is a 35 percent discount from the existing list price of Remicade, the company's comparison commodity.
Tumor necrosis factor (TNF) inhibitors are set to increase in popularity as the prevalence of autoimmune disorders rises around the world. As per the CDC (Centers for Disease Control and Prevention), almost 54.4 million people in the U.S. suffered from arthritis between 2013 and 2015.
Tailored Information as per niche requirement:
LIMITED TIME OFFER - Hurry Up!
Exclusive offer!!! Purchase the report at a discounted rate!!!
Get Discount For Buyers UPTO 30% OFF On Any Research Report
Buy Now with Discount for Premium Report 2021: https://www.coherentmarketinsights.com/promo/buynow/3463
Restraints
As per the NCBI (National Center for Biotechnology Information), about 50 percent of people with autoimmune disorders globally stop taking TNF inhibitors after a year and only 5-10% of people react positively to TNF inhibitors, while the rest have disease action or serious side effects even after treatment with TNF inhibitors. Furthermore, the growth of the global tumor necrosis factor (TNF) inhibitor drugs market is projected to be hampered by the availability of alternative drugs from a different class on the market. In 2017, Pfizer Inc. revealed that tofacitinib (Xeljanz), a Janus kinase inhibitor and a small molecular drug for rheumatoid arthritis, had received FDA approval.
TNF inhibitors have been linked to an increase in the risk of infections of the skin, soft tissues, and joints, as well as an increased risk of cancer in the general population (non-melanoma skin cancers). Other severe side effects, such as osteomyelitis, influenza, sepsis, tuberculosis, and progressive multifocal leukoencephalopathy, can occur as a result of this chronic disease. The above factors are expected to restrain the global tumor necrosis factor (TNF) inhibitors drugs market growth over the forecast period.
Regional Analysis
Due to the rising production and releases of newer products in the region, North America is expected to maintain its dominance in the global tumor necrosis factor (TNF) inhibitor drugs market during the forecast period. Renflexis (biosimilar of infliximab (Remicade)) obtained FDA clearance in 2019 as the first TNF inhibitor in the United States, thanks to a global biosimilars research and commercialization deal between Merck and Samsung Bioepis Co., Ltd.
In addition, Amgen Inc. announced that infliximab-axxq (avsola) received FDA clearance in the United States in 2019 for all accepted indications of the reference medication, infliximab (Remicade). In 2019, Celgene Corporation obtained FDA approval for apremilast (otezla), an oral PDE4 inhibitor for the treatment of adult patients with mouth ulcers (mucositis) diagnosed with Behçet's disease, a rare condition characterised by blood vessel inflammation in the body.
Another factor expected to aid North America's rise in the global tumor necrosis factor (TNF) inhibitor drugs market is the rising prevalence of autoimmune disorders in the population. As per the CDC (Centers for Disease Control and Prevention), about 54.4 million individuals in the U.S. suffered from arthritis in 2017, contributing around 25 percent of the total population, while 1.3 million women, 294,000 people, and 0.6 to 2.4 million people over 15 years of age in the United States, respectively, suffered from rheumatoid arthritis, juvenile arthritis, and spondylarthritides.
To get detailed table of content (ToC), please click - https://www.coherentmarketinsights.com/ongoing-insight/toc/3463
The same source added that around 78 million (26 percent) of adults in the U.S. aged 18 and up will have arthritis by 2040. As a result of the rising prevalence of autoimmune diseases in North America, the tumor necrosis factor (TNF) drugs inhibitor market is projected to rise during the forecast period.
Key Players
Major companies contributing in the global tumor necrotic factor (TNF) inhibitor drugs market include Johnson & Johnson Services, Inc, UCB S.A., AbbVie Inc., d.b.a., Amgen Inc., GlaxoSmithKline plc, Novartis International AG, Inc., Cadila Healthcare Ltd, Bristol-Myers Squibb Company, Sanofi S. A, and Merck & Co.
Market Segmentation
According to the type of drug,
- Etanercept
- Infliximab
- Adalimumab
- Certolizumab
- Golimumab
According to indication,
- Rheumatoid Arthritis
- Juvenile Arthritis
- Psoriatic Arthritis
- Plaque Psoriasis
- Ankylosing Spondylitis
- Ulcerative Colitis
- Crohn's Disease
- Others
According to administration route,
- Subcutaneous Injection
- Intravenous injection
According to channel of distribution,
- Hospital pharmacies
- Retail Pharmacies
- Online Pharmacies
According to region,
- North America
- Latin America
- Europe
- Asia Pacific
- Middle East
- Africa
Other Related Reports:
About Us:
Coherent Market Insights is a global market intelligence and consulting organization focused on assisting our plethora of clients achieve transformational growth by helping them make critical business decisions. We are headquartered in India, having office at global financial capital in the U.S. and sales consultants in United Kingdom and Japan. Our client base includes players from across various business verticals in over 150 countries worldwide. We pride ourselves in catering to clients across the length and width of the horizon, from Fortune 500 enlisted companies, to not-for-profit organization, and startups looking to establish a foothold in the market. We excel in offering unmatched actionable market intelligence across various industry verticals, including chemicals and materials, healthcare, and food & beverages, consumer goods, packaging, semiconductors, software and services, Telecom, and Automotive. We offer syndicated market intelligence reports, customized research solutions, and consulting services.
To know more about us, please visit our website – www.coherentmarketinsights.com
Contact:
Coherent Market Insights
1001 4th Ave, #3200 Seattle, WA 98154, U.S.
Email: sales@coherentmarketinsights.com
United States of America: +1-206-701-6702
United Kingdom: +44-020-8133-4027
Japan: +050-5539-1737
India: +91-848-285-0837
Editor Details
-
Company:
- Coherent Market Insights
-
Name:
- Nirav Gokani
- Email:
-
Telephone:
- +918849480752
- Website:
